Citigroup’s Travere Therapeutics TVTX Stock Holding History

Citigroup’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-500	Closed	-$7K	–	7780
2019 Q4	$7K	Sell	500 -32,500	-98%	-$415K	﹤0.01%	7320
2019 Q3	$382K	Buy	33,000 +800	+2%	+$13.2K	﹤0.01%	4595
2019 Q2	$647K	Buy	32,200 +29,300	+1,010%	+$579K	﹤0.01%	4158
2019 Q1	$66K	Buy	2,900 +100	+4%	+$2.21K	﹤0.01%	6112
2018 Q4	$63K	Sell	2,800 -9,000	-76%	-$224K	﹤0.01%	6046
2018 Q3	$339K	Buy	11,800 +1,800	+18%	+$51.5K	﹤0.01%	4708
2018 Q2	$273K	Buy	+10,000	New	+$266K	﹤0.01%	4737
2017 Q2	–	Sell	-1,500	Closed	-$28K	–	7485
2017 Q1	$28K	Buy	1,500 +1,200	+400%	+$23.5K	﹤0.01%	6077
2016 Q4	$6K	Buy	+300	New	+$6.13K	﹤0.01%	6882

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup's TVTX Position: Q2 2026 in Review

Citigroup increased its Travere Therapeutics (TVTX) stake by 324% in Q2 2026, buying an estimated $3.9M and bringing the position to 115,045 shares worth $6.54M. The position accounts for ﹤0.01% of the portfolio, ranked #1917.

Citigroup first reported a position in TVTX in Q1 2014 and has held it in 50 quarters since. The position peaked at $8.14M in Q1 2023. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Citigroup held 115,045 shares of Travere Therapeutics worth $6.54M as of Q2 2026.
Citigroup bought 87,914 Travere Therapeutics shares in Q2 2026, an estimated $3.9M.
Travere Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1917 holding.
Citigroup first reported a position in Travere Therapeutics in Q1 2014 and has held it in 50 quarters since.
Citigroup's Travere Therapeutics position peaked at $8.14M in Q1 2023.
320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.